The positive initial data from the Phase 2 trial of ZYNLONTA suggests a high response rate in a specific patient group, which could lead to increased demand for the drug if further results continue to be favorable. This has the potential to positively impact ADC Therapeutics' future earnings and stock price as successful clinical trials can lead to drug approvals and increased market share.